Wht signaling and breast cancer

Cancer Biology and Therapy

Volumn 3, Issue 1, 2004, Pages 36-41

  Howe, Louise R ^b   Brown, Anthony M C ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NONE

Author keywords

Breast cancer; Mutations; Pathway; Wnt proteins; Wnt signaling; catenin

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; RNA; WNT PROTEIN; CATNB PROTEIN, MOUSE; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; ONCOPROTEIN; TRANSACTIVATOR PROTEIN;

BREAST CANCER; CARCINOGENESIS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; BETA CATENIN; BREAST NEOPLASMS; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; WNT PROTEINS;

EID: 3142590865     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.1.561     Document Type: Review

References (76)

1. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-305.
2. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653:1-24.
3. Miller JR. The Wnts. Genome Biol 2002; 3: 3001.1-.15.
4. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423:409-14.
5. Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003; 423:448-52.
6. Nusse R, Varmus HE. Wnt genes. Cell 1992; 69:1073-87.
7. Brown AMC. Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res 2001;3:351-5.
8. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-51.
9. Bergstein I, Brown AMC. WNT genes and breast cancer. In: Bowcock AM, ed. Breast Cancer: Molecular Genetics, Pathogenesis and Therapeutics: Humana Press Inc.; 1999:181-98.
10. Kirikoshi H, Sekihara H, Katoh M. Expression of WNT14 and WNT14B mRNAs in human cancer, up-regulation of WNT14 by IFNgamma and up-regulation of WNT14B by beta-estradiol. Int J Oncol 2001; 19:1221-5.
11. Shimizu H, Julius MA, Zheng Z, Giarre M, Brown AMC, Kitajewski J. Mammary cell transformation by Wnt family proteins correlates with regulation of beta-catenin. Cell Growth and Differentiation 1997; 8:1349-58.
12. Bejsovec A. Wnt signaling: An embarrassment of receptors. Curr Biol 2000; 10:R919-R22.
13. Liu G, Bafico A, Harris VK, Aaronson SA. A novel mechanism for Wnt activation of canonical signaling through the LRP6 receptor. Mol Cell Biol 2003; 23:5825-35.
14. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev 1999; 18:15-30.
15. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70.
16. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275:1787-90.
17. Smalley MJ, Dale TC. Wnt signaling and mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2001; 6:37-52.
18. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31:99-109.
19. Nusse R, van Ooyen A, Cox D, Fung YK, Varmus HE. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 1984; 307:131-6.
20. Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P. Delta-N89beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol 2001; 153:555-68.
21. Michaelson JS, Leder P. beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 2001; 20:5093-9.
22. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988; 55:619-25.
23. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 2001; 3:793-801.
24. Lin SY, Xia W, Wang JC, et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000; 97:4262-6.
25. Jonsson M, Borg A, Nilbert M, Andersson T. Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer 2000; 36:242-8.
26. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398:422-6.
27. Candidus S, Bischoff P, Becker KF, Hofler H. No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. Cancer Res 1996; 56:49-52.
28. Schlosshauer PW, Brown SA, Eisinger K, et al. APC truncation and increased beta-catenin levels in a human breast cancer cell line. Carcinogenesis 2000; 21:1453-6.
29. Abraham SC, Reynolds C, Lee JH, et al. Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol 2002; 33:39-46.
30. Sorlie T, Bukholm I, Borresen-Dale AL. Truncating somatic mutation in exon 15 of the APC gene is a rare event in human breast carcinomas. Mutations in brief no. 179. Online. Hum Mutat 1998; 12:215.
31. Mai M, Qian C, Yokomizo A, Smith DI, Liu W. Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23-q24. Genomics 1999; 55:341-4.
32. Webster MT, Rozycka M, Sara E, et al. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 2000; 28:443-53.
33. Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001; 411:321-5.
34. Mao J, Wang J, Liu B, et al. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell 2001; 7:801-9.
35. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002; 346:1513-21.
36. Lejeune S, Huguet EL, Hamby A, Poulsom R, Harris AL. Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1995; 1:215-22.
37. Jonsson M, Dejmek J, Bendahl PO, Andersson T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 2002; 62:409-16.
38. Iozzo RV, Eichstetter I, Danielson KG. Aberrant expression of the growth factor Wnt-5a in human malignancy. Cell Regulation 1995; 55:3495-9.
39. Dale TC, Weber-Hall SJ, Smith K, et al. Compartment switching of WNT-2 expression in human breast tumors. Cell Regulation 1996; 56:4320-3.
40. Ugolini F, Charafe-Jauffret E, Bardou VJ, et al. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 2001; 20:5810-7.
41. Wissmann C, Wild PJ, Kaiser S, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003; 201:204-12.
42. Willert K, Brink M, Wodarz A, Varmus H, Nusse R. Casein kinase 2 associates with and phosphorylates dishevelled. EMBO J 1997; 16:3089-96.
43. Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC. CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling. J Biol Chem 2003; 278:24018-25.
44. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001; 20:3247-57.
45. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? Faseb J 2003;17:349-68.
46. Martinez Arias A, Brown AMC, Brennan K. Wnt signalling: pathway or network? Curr Opin Genet Dev 1999; 9:447-54.
47. Holnthoner W, Pillinger M, Groger M, et al. Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells. J Biol Chem 2002; 277:45847-53.
48. Fukumoto S, Hsieh CM, Maemura K, et al. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 2001; 276:17479-83.
49. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 2002; 277:30935-41.
50. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001; 20:252-9.
51. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998; 95:11211-6.
52. Novak A, Hsu SC, Leung-Hagesteijn C, et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci USA 1998; 95:4374-9.
53. Shibamoto S, Hayakawa M, Takeuchi K, et al. Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes Commun 1994; 1:295-305.
54. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994; 127:1375-80.
55. Kanai Y, Ochiai A, Shibata T, et al. c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 1995; 208:1067-72.
56. Adam L, Vadlamudi RK, McCrea P, Kumar R. Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta -catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J Biol Chem 2001; 276:28443-50.
57. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 2002; 277:22692-8.
58. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 2000; 97:12103-8.
59. Kim K, Lee KY. Tyrosine phosphorylation translocates beta-catenin from cell→cell interface to the cytoplasm, but does not significantly enhance the LEF-1-dependent transactivating function. Cell Biol Int 2001; 25:421-7.
60. Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B, Leonard EJ. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol 2001; 21:5857-68.
61. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003;10:1-21.
62. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29:3-9.
63. Petrocelli T, Slingerland JM. PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res 2001; 3:356-60.
64. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 2001; 153:1161-74.
65. Hashimoto M, Sagara Y, Langford D, et al. Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem 2002; 277:32985-91.
66. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
67. Damalas A, Ben-Ze'ev A, Simcha I, et al. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J 1999; 18:3054-63.
68. Matsuzawa SI, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 2001; 7:915-26.
69. Liu J, Stevens J, Rote CA, et al. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001;7:927-36.
70. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of beta-catenin by activated p53. Mol Cell Biol 2001; 21:6768-81.
71. Wulf GM, Ryo A, Wulf GG, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001; 20:3459-72.
72. Katoh M. Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. Int J Oncol 2001; 19:1003-7.
73. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and diseased breast tissue. Cancer Res 1994; 54:2615-21.
74. Bui TD, Rankin J, Smith K, et al. A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene 1997; 14:1249-53.
75. Ho KY, Kalle WH, Lo TH, Lam WY, Tang CM. Reduced expression of APC and DCC gene protein in breast cancer. Histopathology 1999; 35:249-56.
76. Sawyer EJ, Hanby AM, Rowan AJ, et al. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol 2002;196:437-44.